Cardiovascular & Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore, Singapore.
National Heart Research Institute Singapore, National Heart Centre, Singapore, Singapore.
Cardiovasc Res. 2019 Jun 1;115(7):1143-1155. doi: 10.1093/cvr/cvy286.
The coronary circulation is both culprit and victim of acute myocardial infarction. The rupture of an epicardial atherosclerotic plaque with superimposed thrombosis causes coronary occlusion, and this occlusion must be removed to induce reperfusion. However, ischaemia and reperfusion cause damage not only in cardiomyocytes but also in the coronary circulation, including microembolization of debris and release of soluble factors from the culprit lesion, impairment of endothelial integrity with subsequently increased permeability and oedema formation, platelet activation and leucocyte adherence, erythrocyte stasis, a shift from vasodilation to vasoconstriction, and ultimately structural damage to the capillaries with eventual no-reflow, microvascular obstruction (MVO), and intramyocardial haemorrhage (IMH). Therefore, the coronary circulation is a valid target for cardioprotection, beyond protection of the cardiomyocyte. Virtually all of the above deleterious endpoints have been demonstrated to be favourably influenced by one or the other mechanical or pharmacological cardioprotective intervention. However, no-reflow is still a serious complication of reperfused myocardial infarction and carries, independently from infarct size, an unfavourable prognosis. MVO and IMH can be diagnosed by modern imaging technologies, but still await an effective therapy. The current review provides an overview of strategies to protect the coronary circulation from acute myocardial ischaemia/reperfusion injury. This article is part of a Cardiovascular Research Spotlight Issue entitled 'Cardioprotection Beyond the Cardiomyocyte', and emerged as part of the discussions of the European Union (EU)-CARDIOPROTECTION Cooperation in Science and Technology (COST) Action, CA16225.
冠状动脉循环既是急性心肌梗死的罪魁祸首,也是受害者。心外膜动脉粥样硬化斑块破裂伴血栓形成可导致冠状动脉闭塞,必须去除这种闭塞以诱导再灌注。然而,缺血和再灌注不仅会导致心肌细胞受损,还会导致冠状动脉循环受损,包括碎片的微栓塞和罪犯病变释放可溶性因子、内皮完整性受损导致通透性增加和水肿形成、血小板激活和白细胞黏附、红细胞淤滞、从血管扩张到血管收缩的转变,以及最终导致毛细血管结构损伤,最终导致无复流、微血管阻塞(MVO)和心肌内出血(IMH)。因此,冠状动脉循环是心脏保护的有效靶点,不仅限于保护心肌细胞。几乎所有上述有害终点都已被证明可通过一种或另一种机械或药理学心脏保护干预而得到有利影响。然而,无复流仍然是再灌注心肌梗死的严重并发症,且独立于梗死面积,具有不利的预后。MVO 和 IMH 可通过现代成像技术诊断,但仍有待有效的治疗方法。本文综述了保护冠状动脉循环免受急性心肌缺血/再灌注损伤的策略。本文是题为“超越心肌细胞的心脏保护”的心血管研究重点问题的一部分,是欧盟(EU)-心脏保护合作科学技术(COST)行动 CA16225 讨论的一部分。